Acadian Asset Management LLC Buys 3,460,717 Shares of Pfizer Inc. $PFE

Acadian Asset Management LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 511.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,137,415 shares of the biopharmaceutical company’s stock after buying an additional 3,460,717 shares during the period. Acadian Asset Management LLC owned approximately 0.07% of Pfizer worth $100,284,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Pacer Advisors Inc. grew its position in Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after purchasing an additional 17,957,928 shares during the period. Amundi raised its stake in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new position in Pfizer during the 1st quarter valued at $389,861,000. Goldman Sachs Group Inc. lifted its position in shares of Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after purchasing an additional 9,041,990 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after buying an additional 4,629,976 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. Bank of America boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.18.

Pfizer Stock Down 1.6%

Shares of NYSE PFE opened at $24.45 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market cap of $138.99 billion, a P/E ratio of 13.00, a P/E/G ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The business has a 50-day simple moving average of $24.74 and a two-hundred day simple moving average of $24.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.